Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Greater China Junior Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (319)	10/10/2003 9:46:32 AM
From: Crossy	Read Replies (1) \| Respond to of 1992

re: 1164.HK - Vital Biotech - HK listed - HK$0.64 Business Review The Group is a fully integrated, multinational biopharmaceutical corporation engaged in the research, development, manufacture, sale and distribution of biopharmaceutical and conventional pharmaceutical products. Currently, the Group has business operations in Australia, Hong Kong, Macao and the PRC. With its research and development focus on downstream value adding biotechnology processing systems, the Group develops protein stabilisation and various drug delivery technologies which may be adapted to a wide range of applications, such as, in the areas of cytokines, probiotics and vaccine. In addition, the Group manufactures pharmaceutical products and distributes such products through its extensive distribution network in the PRC. This has provided the Group with a steady income stream during the Track Record Period.During the Track Record Period, the Group has utilised its technologies to develop two products, namely, Opin which was originally developed for treatment of chronic erosive cervicitis by Wuhan Tianao Pharmaceutical Factory and subsequently acquired by the Group through the acquisition of Wuhan Weiao, and Spray-On Bandage, which was originally developed by Mr. Ko for wound protection. The two platform technologies commercialised and refined by the Group are the "Protein Stabilisation and Delivery (PSD)" technology and the polymer membrane based "Skin Drug Delivery System (SDDS)" technology. The PSD technology, jointly invented by Mr. Ko and Mr. Au Yeung, is built on a micro bio-encapsulation process. This allows products to be room temperature stable and enables them to be delivered via a non-injection route, e.g. through various mucosal surface of the body. The SDDS technology, invented by Mr. Ko, is used for delivering various chemical drugs through the skin-surface. Both technologies can be used to develop products for human and veterinary applications.The Group, utilising its research and development capabilities, is co-operating and seeking to co-operate with a number of established pharmaceutical companies. Under such arrangements, the Group assists those companies to improve and expand the applications of their existing pharmaceutical products for existing and emerging markets with the intention of forming a closer business relationship with such companies at a later stage. This can be in the form of joint venture, licensing, service arrangement or joint development.Since 2000, the Group has developed an extensive distribution network of pharmaceutical products in the PRC. Currently, the Group has 28 marketing and liaison offices strategically located in various major cities in the PRC to promote the Group's products and to provide aftersales services. In order to penetrate into the vast PRC market at a faster pace and lower cost, the Group has also appointed distribution agents in the PRC to distribute its products. The Directors believe that the Group is well-positioned to expand its business by utilising its competitive advantages as follows:· proven research and development capabilities; · established and extensive distribution network; · GMP compliant production facilities; · cost effectiveness; · experienced management team; · strategic segregation of functions in different locations; and · unique platform technologies under patent applications. Prospects The Directors anticipate that demand for effective and affordable biopharmaceutical and conventional pharmaceutical products worldwide will continue to grow as a result of the growing worldwide population, improving living standard, longer life expectancy and general availability of data from the Human Genome Program. To capture anticipated growing opportunities, the Directors intend to:· continue to enhance its existing products and develop new products which have significant market potential; · establish strategic alliances for mutually beneficial partnerships; · further enlarge its marketing and distribution network in the PRC; · extend its presence into the international markets; and · expand its production capacity and research and development capabilities Financial Ratios (Currency: HKD) Recent Data (HKD) Price 0.50 Change - High 0.51 Low 0.50 Volume 5,370.00K 52-week High 0.55 52-week Low 0.181 Share-related items Market Capitalization - Shares Outstanding Dividend Information Dividend (HKD) 0.02 Dividend Yield 4.00 Accounting Information Equity per share - EPS (HKD) 0.03 Short-term Debt - Long-term Debt - Total Cash 57.98M Valuation Ratios Price/Equity PE Ratios 14.58 Dividend Payout Ratio 58.32 Income Statements Net Profit 40.59M Turnover 167.97M Profitability Profit Margin 24.17% Other Ratios Return on Assets 14.41% Return on Equity 22.99% Current Ratio 199.58% Long-term Debt/Equity - Debt/Equity Earnings Announcement Interim Results For the 6 months ended Jun 2003, gain attributable to shareholders for the group was HKD$ 24.956 million , a growth of 37.7%. Announcement Date : 2003/08/29 Summary: 6 months ended 30 Jun 2003: HKD$(million) Turnover 125.315 Profit/ (Loss) after Tax & MI 24.956 % change over Last Period + 37.7% EPS/(LPS) - Basic (HKD$ cents) 2.01 - Diluted (HKD$ cents) 1.97 Extraordinary (ETD) Gain/(Loss) N/A Dividend per share (HKD$ cents) 1 (Specify if with other option) with scrip option Special Dividend (HKD$ cents) N/A B/C dates for Final Dividends 15-09-2003 to 19-09-2003 bdi. Payable Date 2003/10/28